Literature DB >> 25431479

Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia.

Varinder Kaur1, Paulette Mehta1, Joyce Johnsurd2, Rangaswamy Govindarajan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25431479     DOI： 10.1182/blood-2014-08-591875

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

Review 1.  Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology.

Authors:  Gabriela Lupușoru; Ioana Ailincăi; Georgiana Frățilă; Oana Ungureanu; Andreea Andronesi; Mircea Lupușoru; Mihaela Banu; Ileana Văcăroiu; Constantin Dina; Ioanel Sinescu
Journal:  Biomedicines       Date:  2022-04-28

Review 2.  Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.

Authors:  Nael Alakel; Jan Moritz Middeke; Johannes Schetelig; Martin Bornhäuser
Journal:  Onco Targets Ther       Date:  2017-02-02       Impact factor: 4.147

Review 3.  Tumor Lysis Syndrome in Patients with Hematological Malignancies.

Authors:  Yohannes Belay; Ketsela Yirdaw; Bamlaku Enawgaw
Journal:  J Oncol       Date:  2017-11-02       Impact factor: 4.375

Review 4.  Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.

Authors:  Bruce D Cheson; Sari Heitner Enschede; Elisa Cerri; Monali Desai; Jalaja Potluri; Nicole Lamanna; Constantine Tam
Journal:  Oncologist       Date:  2017-08-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.